In order to identify prognostic factors for death among cancer patients with fungemia, an 18-month survey of fungemia in patients with cancer was undertaken in three hospitals in Rio de Janeiro. For the assessment of risk factors for death, the following variables were analyzed: age; gender; underlying cancer; last treatment for the underlying disease; previous surgery; use of antibiotics, antifungal agents, steroids, or total parenteral nutrition; use of a central venous catheter; chemotherapy; radiotherapy; presence and duration of neutropenia; etiologic agent of the fungemia; treatment of the fungemia; clinical manifestations; and performance status (Karnofsky score) on the day of the positive blood culture. In multivariate analysis, the variables associated with an increased risk for death were older age, persistent neutropenia, and low performance status. Identifying risk factors for death may help to define a group of high-risk patients for whom new therapeutic options should be tried.
Fungal infections represent a major challenge for those who with Ç500 beds each and a 220-bed referring hospital for cancer patients. Two of these hospitals have bone marrow care for patients with cancer. The frequency of fungal infections has increased substantially in the past decade [1] , and many transplant units, with a total of 12 beds. The cases of fungemia were identified on the basis of positive blood cultures from the risk factors have been identified, including the use of antibiotics, central venous catheterization, neutropenia, and the use of mycology laboratories of the hospitals. The blood cultures were ordered at the discretion of the attending physician. HIV-posimore aggressive chemotherapy [2] . The mortality associated with systemic fungal infections is high. The mortality attributtive patients were excluded. A positive blood culture was defined by the growth of a fungal pathogen in at least one blood able to candidemia in hospitalized patients, including those without cancer, was 38% in a case-control study [3] . Among culture specimen taken from a peripheral vein and/or a central venous catheter. cancer patients, the crude mortality exceeds 70% [4] .
Despite the high mortality, few studies have evaluated possiThe blood samples were inoculated in trypticase soy broth ble factors predictive of death among cancer patients with funor brain-heart infusion medium and examined daily for at least gal infections. In 1994 we started a survey on fungemia in 4 weeks. Blind subcultures were performed after 6 -24 hours cancer patients in three hospitals in Rio de Janeiro, Brazil. The of incubation at 37ЊC or whenever examination of the bottles main objective of this survey was to obtain epidemiological suggested growth of microorganisms. For yeast identification data on fungemia in cancer patients in a developing country, [5] , germ-tube-negative isolates were submitted to an analysis since little information was available. In this article we discuss of morphological and biochemical characteristics, including the influence of several clinical variables on the outcome for the assimilation of carbohydrates and nitrate as well as sugar cancer patients with fungemia and identify prognostic factors.
fermentation. Identification of Candida albicans by the germtube test was confirmed by the presence of chlamidioconidia in cornmeal -Tween 80 agar. Molds were identified according Patients and Methods to the morphological features seen by light microscopy. In 1994 we started a survey on fungemia in cancer patients
The patients' clinical courses were followed until death or in three hospitals in Rio de Janeiro: two university hospitals the resolution of fungemia. A database was organized with use of the software Epi-Info (Epi-Info version 6.0, May 1994; Centers for Disease Control and Prevention, Atlanta), and the [6] and determined weekly by the attending physician. The score closest to the date of the The performance status of the patients was õ40 in 30% of cases, between 40 and 60 in 31%, and ú60 in 39%. Fever was first positive blood culture was considered for the analysis.
Patients were considered neutropenic if they had fewer than the most frequent clinical manifestation (36 patients). Seven patients (13%) presented with signs of shock, and 6 had evi-500 neutrophils/mm 3 . The neutropenia was considered persistent if the neutrophil counts remained lower than 500/mm 3 until dence of deep-seated infection: skin lesions in 5 (2 infections due to Fusarium species, 2 due to Candida tropicalis, and 1 death or until 15 days from the positive blood culture. Shock was defined as a decrease of 30 mm Hg and 20 mm Hg in due to Candida species) and, in the other case, alveolar infiltrates and documentation of pulmonary and renal involvement baseline systolic and diastolic pressures, respectively, for at least 30 minutes.
at autopsy. There were 43 candidemias (38 non-albicans) and 11 other In the assessment of risk factors for death, patients who died were compared with patients who survived the episode of fungemias: 4 due to Rhodotorula rubra, 3 due to Fusarium species, 2 due to Cryptococcus neoformans, 1 due to Wangiella fungemia. The comparison was made initially by univariate analysis, and all variables with a P value of less than 5%
dermatitidis, and 1 due to Aspergillus flavus. The non-albicans species were C. tropicalis in 16, Candida parapsilosis in 6, were entered in a stepwise logistic regression analysis. In the univariate analysis, continuous variables were compared by the Candida guilliermondii in 4, and Candida lusitaniae and Candida stellatoidea in 1 each. In 10 cases of candidemia the Wilcoxon method, and for noncontinuous variables the x 2 test or Fisher's exact test (two-tailed) was used as appropriate.
isolate was not available for species identification. The death rate was 48%, and the median duration of survival after the diagnosis of fungemia was 33 days. Among the different causative species, the associated mortality ranged between Results 44% and 75%, but the differences in mortality were not statistically significant. Fifty-four episodes of fungemia were identified in 54 patients. There were 30 males and 24 females. The median age Table 1 shows the results of the univariate analysis for the assessment of prognostic factors. Older age and low perforwas 18 years (range, 1 -83 years). The underlying diseases were as follows: acute myeloid leukemia in 18 (33%), acute mance status were associated with an increased death rate. In addition, the outcome was poorer for patients whose underlying lymphoid leukemia in 9 (17%), lymphoma in 9 (17%), and solid tumors in 18 (9 carcinomas and 9 sarcomas). Only one disease was considered terminal (P Å .01). Among clinical manifestations, shock was associated with an increased death patient had received a bone marrow transplant (autologous). In 20 patients (37%) the fungemia occurred during early treatrate (P Å .004). The death rate was higher for patients without a central venous catheter than for those with such catheters ment for the underlying disease, and the disease of only nine patients (17%) was considered terminal at the time of the (P Å .01). On the other hand, among patients with central venous access, continued catheterization after the documentafungemia.
Forty-nine patients (91%) were receiving antibiotics at the tion of fungemia was associated with higher mortality (69%, vs. 23% for patients whose catheters were removed; P Å .003). time of onset of the fungemia. Forty-two patients (78%) had a central venous catheter in place (32 tunneled cuffed siliThe absolute number of neutrophils was not a predictive factor for death, but among the neutropenic patients, the persistence cone catheters and 10 nontunneled). Neutropenia (õ500 neutrophils/mm 3 ) was noted in 26 patients (48%). The neutroof neutropenia was associated with a higher death rate (P Å .001). Antifungal treatment had no influence on the death penia persisted throughout the episode of fungemia in 19 (76%) of the 26 neutropenic patients. Other risk factors noted rate (P Å .89). As shown in table 2, the prognostic factors for death in the were use of steroids (17 patients), surgery (12 patients), and use of total parenteral nutrition (4 patients). Antifungal multivariate analysis were low performance status (P õ .0001), older age (P Å .0001), and persistent neutropenia (P Å .003). prophylaxis had been administered to eight patients (15%). The antifungal agent was itraconazole for five patients and oral nistatin, iv amphotericin B (low dose), and fluconazole Discussion in one patient each.
Neutropenia was more frequent in patients with leukemia The frequency of fungemia among cancer patients has increased substantially in the past decade [7] . Indeed, Candida and lymphoma than in patients with solid tumors (67% vs. 11%; P Å .0001). The use of steroids was also more common species are some of the most frequent pathogens in bloodstream infections, regardless of the underlying disease [8] . In the presamong patients with hematologic malignancies (39% vs. 17%; P Å .09). On the other hand, 50% of patients with solid tumors ent study, Candida species were also the most frequent causes of fungemia, but contrary to the situation at many other centers had undergone surgery, compared with only 8% of patients with hematologic malignancies (P Å .001). Use of antibiotics [1, 9] , non-albicans species accounted for the great majority / 9c51$$jy10 06-15-98 22:59:06 cida UC: CID of cases. Even considering that in 10 cases the strains were have many of the known risk factors for candidemia, including previous surgery, catheters, and the use of antibiotics. Furthernot available for further species identification, all those strains more, the proportion of patients with solid tumors who have were germ-tube-negative, and that test is reliable for discrimireceived aggressive chemotherapy has increased in the past nating between C. albicans and non-albicans species [10] .
decade, rendering these patients more prone to develop neutroThe apparent increase in the frequency of non-albicans spepenia. In our survey, however, neutropenia was much more cies reported in many centers in developed countries seems to common among patients with hematologic malignancies and be related to the increased use of azoles in those countries occurred in only 11% of patients with solid tumors. [11 -13] . In our study, only six patients were receiving an azole Therefore, it seems that risk factors other than neutropenia before the development of the fungemia. In a large multicenter played a major role in the development of fungemia in our survey of candidemia in tertiary hospitals in Brazil, we also patients with solid tumors. One of these risk factors may be observed a high predominance of non-albicans species despite surgery, which was far more frequent for patients with solid the rare use of azoles [14] . Therefore, it seems that in Brazil tumors than for patients with hematologic malignancies. The non-albicans species predominate, and this phenomenon is not reason why surgery predisposes to the development of related to azole use.
fungemia is presumed to be multifactorial. Yeast colonization In the present study, a solid tumor was present in 33% of of the gratrointestinal tract due to the use of broad-spectrum the patients with fungemia. In a survey of fungemia in cancer antibiotics, followed by migration of these colonizing fungi to patients, conducted by the European Organization for Research the bloodstream owing to disruption of the mucosal barrier, is and Treatment of Cancer ( EORTC ) [15] , the proportion of one of these factors [16] . In addition, surgical patients have patients with solid tumors was 34%. Patients with solid tumors central venous catheters and receive parenteral nutrition, which are additional risk factors for fungemia [17] . Neutropenia is one of the most important risk factors for In the present study only 17% of the patients with fungemia , 21% of the patients were with neutropenia, the persistence of this risk factor was associated with a poorer outcome in both the univariate and multivariconsidered to have terminal disease, and 25% were in the initial stage of treatment. Therefore, it seems that in almost 50% of ate analyses. These findings highlight the importance of the recovery of the host defenses in the outcome of systemic fungal cases the patients are not neutropenic, and the fungemia is not limited to patients with uncontrolled underlying cancer. This infections, even more so than the antifungal treatment administered [25] . might have important implications for the treatment of the underlying disease, and attempts to prevent the occurrence of Another variable identified in the multivariate analysis was older age. The median age of survivors was 7 years, and that fungemia are certainly warranted.
Among the non-albicans species, C. glabrata is considered of the nonsurvivors, 50 years. This finding may be explained by the fact that children are presumed to respond better than an emerging pathogen [1] . In a review article it was the third most frequent species [20] . In our study there was no fungemia adults to the stress of aggressive chemotherapy, mucositis, and surgery. Therefore, it is possible that prognostic factors in childue to C. glabrata, although in 10 cases we could not identify the species. In our multicenter survey of candidemia in tertiary dren with fungemia are different from those in adults. The influence of increasing age on the prognosis of fungemia was hospitals [14] , candidemia was due to C. glabrata in four (3.4%) of 143 episodes. In only one patient was the underlying also reported in other studies [24] . The performance status was the other variable identified in disease a cancer. Therefore, it seems that C. glabrata is not an emerging pathogen causing candidemia in Brazil.
the multivariate analysis. The Karnofsky scale is an easy and reproducible score index to assess a patient's performance staThe mortality among patients with fungemia is high. The crude mortality for nosocomial candidemia is 70%, and the tus. The highest score is given to patients with no symptoms, and the worst to patients confined to bed and moribund. The estimated attributable mortality is 38% [3] . Among cancer patients the mortality may be even higher. In the present study Karnofsky scale is widely used for cancer patients and is correlated with the chance of complete remission. the overall mortality was 48%. Fifteen patients did not receive antifungal treatment. Since this study was observational, we Other score indexes have been evaluated in stratifying prognostic groups in fungemia. Abi-Said et al. [26] tested the Acute cannot ascertain the reasons why these patients were not treated. Possible reasons include early death (because of a high Physiology and Chronic Health Evaluation (APACHE) III and Sensory Action Potential scores for cancer patients and found fungal burden) or a delay in the diagnosis due to the fastidious growth of some fungi. In the analysis of risk factors for death, them to be useful predictors of both the outcome of candidemia and the in-hospital mortality for cancer patients with candideantifungal treatment had no impact on survival. This observation is in agreement with other reports [18, 21] . mia. Nguyen et al.
[24] used a scale based on mental status, presence or absence of fever, hypotension, mechanical ventilaThe influence of a central venous catheter and its removal on the prognosis of fungemia has been discussed in many tion, and cardiac arrest and found it to have a good correlation with the outcome in multivariate analysis. Likewise, in another studies [22, 23] . In a prospective study, Nguyen et al. [24] found that catheter-related candidemias had a better outcome study of candidemia in a tertiary care hospital, higher mortality was associated with higher APACHE II scores [17] . Therefore, than did non-catheter-related candidemias. However, this difference was significant only in the univariate analysis. In the it seems that all these scores are good markers for a group of patients with a high risk for death. present study we observed the same result. A possible explanation is that in many patients with a central venous catheter, In summary, persistent neutropenia, older age, and poor performance status were predictive of death for patients with the device was the source of fungemia, and its removal was immediately beneficial to the patient. On the other hand, in fungemia. The application of the performance status scale to cancer patients with fungemia might help define a group of patients without a catheter, the source of the fungemia was possibly the gastrointestinal tract and therefore much harder to high-risk patients for whom new therapeutic options should be tried. obviate.
As in the study by Nguyen et al.
[24], we found that retaining the catheter was associated with a poorer outcome, at least in the univariate analysis. Since in both studies removal of the
